First-in-Human Trial

Risks & contraindications

Evidence quality

Highlighted claims

• A first-in-human trial tested selective sFlt-1 removal in preterm pre-eclampsia. — A new treatment for preterm pre-eclampsia could benefit mother and child
• The central reported advance is critical safety data rather than a broad efficacy claim. — A new treatment for preterm pre-eclampsia could benefit mother and child
• The supplied article preview does not provide detailed trial numbers or outcomes. — A new treatment for preterm pre-eclampsia could benefit mother and child
• The trial’s significance lies in testing whether selective sFlt-1 removal can be performed without unacceptable risk in pregnant patients with preterm pre-eclampsia. — A new treatment for preterm pre-eclampsia could benefit mother and child